Lilly Hopes To Score Novel Compounds Early By Offering To Screen Discoveries
This article was originally published in The Pink Sheet Daily
Phenotypic Drug Discovery program is open to academia, private research labs and biotechs that could receive a report card or a deal.
You may also be interested in...
A McKinsey & Company white paper highlights the potential for big data gathered from across the health care spectrum to revolutionize pharma R&D.
Repurposing opportunities are unlikely in this NCATS/Lilly project, which has the loftier goal of furthering understanding of how small molecule drugs actually work in complex human systems in order to improve drug development for the entire “research universe.”
Eli Lilly & Co., which like many big pharmas faces patent expiries and an uncertain late-stage pipeline, has worked to improve ties with the venture and academic communities to help spur access to early-stage and less expensive assets.